SCHEMBL20239153

SCHEMBL20239153

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(Cl)cn3)cc(N(C)c3ccc(OC)cc3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.43
VNN1 O95497 6/20 0.39
KDM4E B2RXH2 1/20 0.36
CLK1 P49759 2/20 0.36
CLK2 P49760 2/20 0.36
DYRK1A Q13627 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
DYRK1B Q9Y463 2/20 0.36
ESR1 P03372 2/20 0.35
TUBB4A P04350 2/20 0.35
TUBB P07437 2/20 0.35
TUBA3C P0DPH7 2/20 0.35
TUBA1B P68363 2/20 0.35
TUBA4A P68366 2/20 0.35
TUBB4B P68371 2/20 0.35
TUBB3 Q13509 2/20 0.35
TUBB2A Q13885 2/20 0.35
TUBB8 Q3ZCM7 2/20 0.35
TUBA3E Q6PEY2 2/20 0.35
TUBA1A Q71U36 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18249759 0.86 DGAT2 (0.49) DGAT2VNN1KDM4ECLK1CLK2
SCHEMBL20239154 0.85 DGAT2 (0.46) DGAT2VNN1KDM4ECLK1CLK2
SCHEMBL20472860 0.84 VNN1 (0.38) DGAT2VNN1CLK1CLK2DYRK1A
SCHEMBL20239157 0.83 ALDH1A1 (0.36) ESR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL28895887 0.82 VNN1 (0.41) VNN1SMN1; SMN2MCOLN3MAP2K7
SCHEMBL20472856 0.82 VNN1 (0.42) VNN1SMN1; SMN2MCOLN3CYP2C9MAP2K7
SCHEMBL20239261 0.81 DGAT2 (0.51) DGAT2VNN1KDM4ECLK1CLK2
SCHEMBL20239144 0.79 SIRT2 (0.38) ESR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20239227 0.78 DGAT2 (0.56) DGAT2VNN1KDM4ECLK1CLK2
SCHEMBL28427913 0.76 CA12 (0.46) DGAT2VNN1SMN1; SMN2MCOLN3MAP2K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885VNN1 3148/4885KDM4E 4070/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885VNN1 3615/4885KDM4E 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.